skinny.

Latest / The HemOnc Pulse

Editor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir Fathi

In this Editor’s Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction.

Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient setting while maintaining effectiveness. He also shares insights on promising triplet regimens…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.